DRUG_NAME,STRUCT_ID,TARGET_NAME,TARGET_CLASS,ACCESSION,GENE,SWISSPROT,ACT_VALUE,ACT_UNIT,ACT_TYPE,ACT_COMMENT,ACT_SOURCE,RELATION,MOA,MOA_SOURCE,ACT_SOURCE_URL,MOA_SOURCE_URL,ACTION_TYPE,TDL,ORGANISM,NEW_ID
adenosine,90,Glyceraldehyde-3-phosphate dehydrogenase liver,Enzyme,P04406,GAPDH,G3P_HUMAN,4.46,,IC50,Tested for the inhibitory activity against Glycosomal glyceraldehyde 3-phosphate dehydrogenase (gGAPDH) of human erythrocyte,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:4141
adenosine triphosphate,91,Heat shock cognate 71 kDa protein,Unclassified,P11142,HSPA8,HSP7C_HUMAN,4.76,,IC50,PUBCHEM_BIOASSAY: In Vitro Hsc70 Dose Response Fluorescence Polarization Assay. (Class of assay: confirmatory) [Related pubchem assays: 1072 ],CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:5241
adenosine triphosphate,91,Heat shock 70 kDa protein 1A,Unclassified,P0DMV8,HSPA1A,HS71A_HUMAN,5.47,,IC50,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:5232
alfentanil,114,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.5,,EC50,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL634,AGONIST,Tclin,Homo sapiens,HGNC:8156
alvimopan,143,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.398,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL270190,ANTAGONIST,Tclin,Homo sapiens,HGNC:8156
amiodarone,176,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.112,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
amodiaquine,186,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,5.4,,IC50,Modulation of human wild-type APP695 expressed in SH-SY5Y cells assessed as inhibition of amyloid beta (1 to 40 residues) production measured after 24 hrs,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
anileridine,220,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,,WOMBAT-PK,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201347,AGONIST,Tclin,Homo sapiens,HGNC:8156
astemizole,249,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.218,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
astemizole,249,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.218,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
bacitracin,281,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.269,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
bortezomib,391,26S proteasome non-ATPase regulatory subunit 1,Cytosolic other,Q99460,PSMD1,PSMD1_HUMAN,7.745,,Ki,,WOMBAT-PK,=,,,,,,Tbio,Homo sapiens,HGNC:9554
bortezomib,391,Lysosomal protective protein,Enzyme,P10619,CTSA,PPGB_HUMAN,5.04,,IC50,Inhibition of recombinant cathepsin A (unknown origin) using Mca-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH as substrate incubated with enzyme for 5 mins prior to substrate challenge for 2 hrs by spectrofluorometer analysis,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:9251
bortezomib,391,Proteasome subunit beta type-1,Enzyme,P20618,PSMB1,PSB1_HUMAN,7.28,,IC50,Reversible inhibition of human erythrocyte derived 20S proteasome subunit beta1 after 30 mins by fluorogenic assay,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL325041,INHIBITOR,Tclin,Homo sapiens,HGNC:9537
bortezomib,391,Proteasome subunit beta type-2,Enzyme,P49721,PSMB2,PSB2_HUMAN,6.23,,IC50,Reversible inhibition of human erythrocyte derived 20S proteasome subunit beta2 after 30 mins by fluorogenic assay,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL325041,INHIBITOR,Tclin,Homo sapiens,HGNC:9539
buprenorphine,434,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.29,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL511142,PARTIAL AGONIST,Tclin,Homo sapiens,HGNC:8156
butorphanol,454,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.92,,Ki,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL33986,PARTIAL AGONIST,Tclin,Homo sapiens,HGNC:8156
candesartan cilexetil,475,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.48,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
carmofur,511,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,5.213,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
carvedilol,522,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,4.52,,IC50,,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
cefapirin,575,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.34,,IC50,,WOMBAT-PK,=,,,,,,Tclin,Homo sapiens,HGNC:8156
cerulenin,578,Fatty acid synthase,Enzyme,P49327,FASN,FAS_HUMAN,5.24,,IC50,Inhibition of human FAS assessed as synthesis of long chain fatty acids from malonyl CoA after 60 mins by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3594
chloroquine,607,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,5.16,,IC50,Modulation of human wild-type APP695 expressed in SH-SY5Y cells assessed as inhibition of amyloid beta (1 to 40 residues) production measured after 24 hrs,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
chlorpromazine,621,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.233,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
chlorpromazine,621,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.54,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
cianidanol,629,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,4.48,,IC50,Inhibition of wild type Amyloid beta (1 to 42) (unknown origin) aggregation by Thioflavin-T fluorescence assay,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
cianidanol,629,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,4.48,,IC50,Inhibition of wild type Amyloid beta (1 to 42) (unknown origin) aggregation by Thioflavin-T fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:620
cinnarizine,654,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.035,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
clioquinol,681,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,4.0,,IC50,Inhibition of amyloid beta (1 to 42) aggregation (unknown origin) at 4:1 compound to protein concentration after 48 hrs by thioflavin T fluorescence assay,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
clomifene,700,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.979,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
clotrimazole,719,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.136,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
clotrimazole,719,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.159,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
clotrimazole,719,Transitional endoplasmic reticulum ATPase,Enzyme,P55072,VCP,TERA_HUMAN,5.85,,IC50,Inhibition of p97 in human HeLa cells assessed as reduction in p97-dependent UbG76V-GFP degradation incubated for 1 hr by luciferase reporter gene assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:12666
clotrimazole,719,Transitional endoplasmic reticulum ATPase,Enzyme,P55072,VCP,TERA_HUMAN,5.85,,IC50,Inhibition of p97 in human HeLa cells assessed as reduction in p97-dependent UbG76V-GFP degradation incubated for 1 hr by luciferase reporter gene assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:12666
clozapine,722,Calmodulin-1,Cytosolic other,P0DP23,CALM1,CALM1_HUMAN,4.7,,IC50,Binding affinity to CaM (unknown origin) by equilibrium dialysis method,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:1442
codeine,725,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.14,,Ki,Displacement of [3H]diprenorphine from recombinant mu opioid receptor expressed in C6 cells,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL485,AGONIST,Tclin,Homo sapiens,HGNC:8156
colchicine,726,Tubulin beta chain,Structural,P07437,TUBB,TBB5_HUMAN,5.24,,Ki,,WOMBAT-PK,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:20778
cycloserine,759,"Glutamate receptor ionotropic, NMDA 2B",Ion channel,Q13224,GRIN2B,NMDE2_HUMAN,5.64,,IC50,,WOMBAT-PK,=,,,,,,Tclin,Homo sapiens,HGNC:4586
cycloserine,759,"Glutamate receptor ionotropic, NMDA 1",Ion channel,Q05586,GRIN1,NMDZ1_HUMAN,5.26,,IC50,,WOMBAT-PK,=,,,,,,Tclin,Homo sapiens,HGNC:4584
cyproterone acetate,766,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.053,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
dactinomycin,774,Growth factor receptor-bound protein 2,Cytosolic other,P62993,GRB2,GRB2_HUMAN,5.3,,IC50,Inhibition of GST-Grb2 Tyrosine kinase SH2 domain binding to [3H]labeled-phosphopeptide (Ac-SpYVNK-NH-C(O)-CH2CH2H3),CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:4566
dactinomycin,774,Growth factor receptor-bound protein 2,Cytosolic other,Q60631,Grb2,GRB2_MOUSE,5.3,,IC50,In vitro binding assay of Shc-derived phosphopeptide to Growth factor receptor bound protein 2 SH2 in B104-1-1 cells was determined,CHEMBL,=,,,,,,,Mus musculus,MGI:95805
danazol,779,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.243,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
dasatinib,785,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.1,,Kd,Binding constant for EGFR(G719S) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
dasatinib,785,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,4.46,,IC50,Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3942
dasatinib,785,Serine/threonine-protein kinase NLK,Kinase,Q9UBE8,NLK,NLK_HUMAN,6.59,,Kd,Binding constant for full-length NLK,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29858
dextropropoxyphene,844,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,,WOMBAT-PK,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213351,AGONIST,Tclin,Homo sapiens,HGNC:8156
dezocine,847,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,7.42,,EC50,Agonist activity at human cloned mu opioid receptor by [35S]GTPgammaS binding assay,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1685,PARTIAL AGONIST,Tclin,Homo sapiens,HGNC:8156
diacerein,849,Caspase-3,Enzyme,P42574,CASP3,CASP3_HUMAN,5.1,,EC50,"PUBCHEM_BIOASSAY: Absorbance-based biochemical high throughput dose response assay for activators of procaspase-3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463141, AID463197, AID463210, AID488941, AID488954, AID493114, AID493115, AID504328, AID504330]",CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:1504
diethylstilbestrol,875,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.63,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
difenoxin,878,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,Mechanism of Action; CHEMBL233; SINGLE PROTEIN,CHEMBL,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201321,AGONIST,Tclin,Homo sapiens,HGNC:8156
alpha-Ergocryptine,885,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.007,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
dihydrocodeine,886,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,Mechanism of Action; CHEMBL233; SINGLE PROTEIN,CHEMBL,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1595,AGONIST,Tclin,Homo sapiens,HGNC:8156
dihydroergocristine,887,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.462,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
diphenoxylate,918,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,7.167,,IC50,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201294,AGONIST,Tclin,Homo sapiens,HGNC:8156
disulfiram,928,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.846,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
disulfiram,928,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,5.821,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
dobutamine,937,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.256,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
docetaxel,939,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.086,,Kd,,WOMBAT-PK,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
domperidone,945,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.766,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
ebastine,977,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.253,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
econazole,983,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.636,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
econazole,983,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.489,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
econazole,983,Neuropeptide Y receptor type 2,GPCR,P49146,NPY2R,NPY2R_HUMAN,4.959,,Ki,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:7957
edetic acid,987,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,5.11,,IC50,Inhibition of amyloid beta aggregation (unknown origin) after 4 hrs by thioflavin S assay in presence of Zn2+,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
erlotinib,1045,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.22,,IC50,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1079742,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
ethinylestradiol,1082,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,4.964,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
everolimus,1118,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,8.7,,IC50,,IUPHAR,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:3942
famotidine,1129,Heat shock protein HSP 90-alpha,Cytosolic other,P07900,HSP90AA1,HS90A_HUMAN,5.304,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:5253
felbamate,1140,"Glutamate receptor ionotropic, NMDA 2B",Ion channel,Q13224,GRIN2B,NMDE2_HUMAN,4.284,,IC50,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1094,ANTAGONIST,Tclin,Homo sapiens,HGNC:4586
fentanyl,1164,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.001,,EC50,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL596,AGONIST,Tclin,Homo sapiens,HGNC:8156
fentanyl,1164,Mu-type opioid receptor,GPCR,P42866,Oprm1,OPRM_MOUSE,8.23,,Ki,,CHEMBL,=,,,,,,,Mus musculus,MGI:97441
flunarizine,1200,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.62,,IC50,Binding affinity against mu opioid receptor using [3H]DAMGO,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8156
fluphenazine,1212,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.075,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
fluphenazine,1212,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.397,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
formoterol,1239,Heat shock protein HSP 90-alpha,Cytosolic other,P07900,HSP90AA1,HS90A_HUMAN,8.523,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:5253
ganciclovir,1277,Metabotropic glutamate receptor 1,GPCR,Q13255,GRM1,GRM1_HUMAN,6.05,,Ki,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:4593
gefitinib,1282,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.4,,Ki,Inhibition of EGFR,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL939,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
gefitinib,1282,Serine/threonine-protein kinase NLK,Kinase,Q9UBE8,NLK,NLK_HUMAN,5.38,,Kd,Binding constant for NLK kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29858
glutamic acid,1310,Metabotropic glutamate receptor 1,GPCR,Q13255,GRM1,GRM1_HUMAN,6.6,,Ki,Displacement of [3H]quisqualate from mGluR1 receptor expressed in BHK cells,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:4593
haloperidol,1353,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.003,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
hesperetin,1362,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.1,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
hesperetin,1362,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.1,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
hexachlorophene,1364,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.126,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
hexachlorophene,1364,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,5.605,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
hexachlorophene,1364,Transitional endoplasmic reticulum ATPase,Enzyme,P55072,VCP,TERA_HUMAN,5.26,,IC50,"PUBCHEM_BIOASSAY: Dose response biochemical high throughput screening assay for inhibitors of the p97 ATPase. (Class of assay: confirmatory) [Related pubchem assays: 1481, 1517 ]",CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:12666
hexachlorophene,1364,Heat shock cognate 71 kDa protein,Unclassified,P11142,HSPA8,HSP7C_HUMAN,4.56,,IC50,PUBCHEM_BIOASSAY: High Throughput Screening Assay for Hsc70 Inhibitors. (Class of assay: confirmatory) ,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:5241
hexachlorophene,1364,Heat shock 70 kDa protein 1A,Unclassified,P0DMV8,HSPA1A,HS71A_HUMAN,4.72,,IC50,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:5232
hydrocodone,1386,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.02,,Ki,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1457,AGONIST,Tclin,Homo sapiens,HGNC:8156
hydromorphone,1393,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.55,,Ki,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL398707,AGONIST,Tclin,Homo sapiens,HGNC:8156
ifenprodil,1419,"Glutamate receptor ionotropic, NMDA 2B",Ion channel,Q13224,GRIN2B,NMDE2_HUMAN,7.7,,IC50,Inhibition of NMDA receptor GluN2B subunit (unknown origin),CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:4586
imatinib,1423,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.12,,Kd,"Binding constant for EGFR(L747-E749del, A750P) kinase domain",CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
diiodohydroxyquinoline,1457,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.724,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
diiodohydroxyquinoline,1457,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,5.279,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
fluostigmine,1494,Lysosomal protective protein,Enzyme,P10619,CTSA,PPGB_HUMAN,5.0,,IC50,Inhibition of recombinant CatA using [14C]GS-7340 substrate,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:9251
ketobemidone,1526,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.0,,EC50,,WOMBAT-PK,=,,,,,,Tclin,Homo sapiens,HGNC:8156
lansoprazole,1547,Fatty acid synthase,Enzyme,P49327,FASN,FAS_HUMAN,5.28,,Ki,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3594
lapatinib,1548,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.04,,Kd,Binding constant for EGFR(G719C) kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201179,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
levallorphan,1560,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.32,,Ki,Displacement of [125I]-IBOxyA from MOR-1 expressed in CHO cells,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1254682,ANTAGONIST,Tclin,Homo sapiens,HGNC:8156
levodopa,1567,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.541,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
levomethadyl acetate,1571,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,,WOMBAT-PK,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1514,AGONIST,Tclin,Homo sapiens,HGNC:8156
levorphanol,1574,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.68,,Ki,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2062261,AGONIST,Tclin,Homo sapiens,HGNC:8156
levorphanol,1574,Mu-type opioid receptor,GPCR,P42866,Oprm1,OPRM_MOUSE,9.52,,Ki,Binding affinity for mouse opioid receptor mu,CHEMBL,=,,,,,,,Mus musculus,MGI:97441
loperamide,1599,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.824,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL841,AGONIST,Tclin,Homo sapiens,HGNC:8156
loperamide,1599,"Glutamate receptor ionotropic, NMDA 2B",Ion channel,Q13224,GRIN2B,NMDE2_HUMAN,,,,,WOMBAT-PK,,,,,,,Tclin,Homo sapiens,HGNC:4586
memantine,1679,"Glutamate receptor ionotropic, NMDA 1",Ion channel,Q05586,GRIN1,NMDZ1_HUMAN,5.02,,IC50,Inhibition of NMDA NR1/NR2B receptor expressed in xenopus oocytes assessed as inhibition of NMDA and glycine-induced current response by two-electrode voltage clamp assay,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1699,NEGATIVE ALLOSTERIC MODULATOR,Tclin,Homo sapiens,HGNC:4584
pethidine,1690,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.04,,Ki,Inhibition of [3H]DAMGO binding to mu-opioid receptor,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL607,AGONIST,Tclin,Homo sapiens,HGNC:8156
meptazinol,1706,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.06,,EC50,,WOMBAT-PK,=,1.0,SCIENTIFIC LITERATURE,,https://pubmed.ncbi.nlm.nih.gov/6141283,PARTIAL AGONIST,Tclin,Homo sapiens,HGNC:8156
methadone,1728,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.78,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL651,AGONIST,Tclin,Homo sapiens,HGNC:8156
acetylmethadol,1729,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,Mechanism of Action,SCIENTIFIC LITERATURE,,1.0,KEGG DRUG,https://pubmed.ncbi.nlm.nih.gov/19153939,http://www.kegg.jp/entry/D04973,AGONIST,Tclin,Homo sapiens,HGNC:8156
methyldopa,1762,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.282,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
methylthioninium chloride,1763,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,6.26,,IC50,,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
naltrexone,1765,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.38,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL19019,ANTAGONIST,Tclin,Homo sapiens,HGNC:8156
naltrexone,1765,Mu-type opioid receptor,GPCR,P42866,Oprm1,OPRM_MOUSE,9.58,,Ki,Displacement of [3H]DAMGO from mouse mu opioid receptor in whole brain without cerebellum,CHEMBL,=,,,,,,,Mus musculus,MGI:97441
miconazole,1800,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.609,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
miconazole,1800,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.534,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
midodrine,1803,Heat shock protein HSP 90-alpha,Cytosolic other,P07900,HSP90AA1,HS90A_HUMAN,7.699,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:5253
mifepristone,1805,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.001,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
miltefosine,1810,RAC-alpha serine/threonine-protein kinase,Kinase,P31749,AKT1,AKT1_HUMAN,5.02,,IC50,Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:391
mitoxantrone,1821,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.269,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
montelukast,1836,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.495,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
morphine,1845,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,7.86,,EC50,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL70,AGONIST,Tclin,Homo sapiens,HGNC:8156
morphine,1845,Mu-type opioid receptor,GPCR,P42866,Oprm1,OPRM_MOUSE,8.92,,Ki,Displacement of [3H]DAMGO from mu opioid receptor in CD1 mouse brain membranes after 1 hr by liquid scintillation counting,CHEMBL,=,,,,,,,Mus musculus,MGI:97441
nalbuphine,1874,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.8,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL895,AGONIST,Tclin,Homo sapiens,HGNC:8156
nalmefene,1876,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.53,,Kd,Activity at human mu opioid receptor by [35S]GTPgammaS binding assay,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL982,ANTAGONIST,Tclin,Homo sapiens,HGNC:8156
nalorphine,1877,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.72,,Ki,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8156
naloxone,1878,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.81,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1718,ANTAGONIST,Tclin,Homo sapiens,HGNC:8156
naloxone,1878,Mu-type opioid receptor,GPCR,P42866,Oprm1,OPRM_MOUSE,9.0,,Ki,,IUPHAR,=,,,,,ANTAGONIST,,Mus musculus,MGI:97441
nelfinavir,1893,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.232,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
nelfinavir,1893,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.255,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
nelfinavir,1893,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,4.648,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
niclosamide,1912,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.98,,IC50,Inhibition of EGFR after 60 mins by radiometric assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
niclosamide,1912,RAC-alpha serine/threonine-protein kinase,Kinase,P31749,AKT1,AKT1_HUMAN,4.23,,IC50,Inhibition of Akt1 after 60 mins by radiometric assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:391
octreotide,1980,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,7.921,,Ki,,PDSP,,,,,,,Tclin,Homo sapiens,HGNC:8156
omapatrilat,1989,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,6.7,,IC50,Inhibition of APP (unknown origin),CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
omapatrilat,1989,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,6.7,,IC50,Inhibition of APP (unknown origin),CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:620
omeprazole,1990,Fatty acid synthase,Enzyme,P49327,FASN,FAS_HUMAN,5.47,,Ki,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3594
orlistat,1996,Fatty acid synthase,Enzyme,P49327,FASN,FAS_HUMAN,5.33,,IC50,Inhibition of human FAS thioster domain preincubated for 30 mins followed by 4-methylumbelliferyl heptanoate substrate addition measured every 5 mins for 60 mins by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3594
oxycodone,2029,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,7.796,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL656,AGONIST,Tclin,Homo sapiens,HGNC:8156
oxycodone,2029,Mu-type opioid receptor,GPCR,P42866,Oprm1,OPRM_MOUSE,6.8,,EC50,Agonist activity at mouse MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay,CHEMBL,=,,,,,,,Mus musculus,MGI:97441
oxymorphone,2034,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.444,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL963,AGONIST,Tclin,Homo sapiens,HGNC:8156
oxymorphone,2034,Mu-type opioid receptor,GPCR,P42866,Oprm1,OPRM_MOUSE,8.3,,Ki,Displacement of [3H]-DAMGO from mouse MOR expressed in HEK293 cells,CHEMBL,=,,,,,,,Mus musculus,MGI:97441
paclitaxel,2044,Tubulin beta chain,Structural,P07437,TUBB,TBB5_HUMAN,8.05,,EC50,,IUPHAR,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:20778
pantoprazole,2054,Fatty acid synthase,Enzyme,P49327,FASN,FAS_HUMAN,5.39,,Ki,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3594
penfluridol,2080,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.06,,Ki,Displacement of [3H]DAMGO from human MOR expressed in HEK cells by radioligand binding assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8156
perhexiline,2106,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.828,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
phenazocine,2119,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.7,,Ki,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8156
phenazocine,2119,Mu-type opioid receptor,GPCR,P42866,Oprm1,OPRM_MOUSE,8.1,,IC50,Ability to induce 50% of maximal effect in mouse vas deferens expressing Opioid receptor delta 1,CHEMBL,=,,,,,,,Mus musculus,MGI:97441
phenelzine,2123,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.75,,Ki,Inhibition of LSD1,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
pimozide,2172,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.43,,IC50,Binding affinity against mu opioid receptor using [3H]DAMGO,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8156
primaquine,2266,Heat shock protein HSP 90-alpha,Cytosolic other,P07900,HSP90AA1,HS90A_HUMAN,8.222,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:5253
promethazine,2286,Calmodulin-1,Cytosolic other,P0DP23,CALM1,CALM1_HUMAN,4.22,,IC50,Binding affinity to CaM (unknown origin) by equilibrium dialysis method,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:1442
propiram,2299,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,Mechanism of Action,WOMBAT-PK,,1.0,SCIENTIFIC LITERATURE,,https://pubmed.ncbi.nlm.nih.gov/7693433,AGONIST,Tclin,Homo sapiens,HGNC:8156
rabeprazole,2350,Fatty acid synthase,Enzyme,P49327,FASN,FAS_HUMAN,5.23,,Ki,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3594
raloxifene,2351,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.321,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
remifentanil,2363,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,,WOMBAT-PK,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1005,AGONIST,Tclin,Homo sapiens,HGNC:8156
reserpine,2370,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.773,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
ritonavir,2391,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,4.575,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
saquinavir,2422,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.408,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
sirolimus,2446,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,10.0,,IC50,Inhibition of mTOR kinase expressed in human HEK293 cells by Western blot analysis,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3942
sorafenib,2459,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.53,,IC50,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
sorafenib,2459,Cyclin-dependent-like kinase 5,Kinase,Q00535,CDK5,CDK5_HUMAN,5.21,,Kd,Average Binding Constant for CDK5; NA=Not Active at 10 uM,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:1774
sorafenib,2459,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,7.74,,IC50,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:6877
sorafenib,2459,Serine/threonine-protein kinase NLK,Kinase,Q9UBE8,NLK,NLK_HUMAN,6.19,,Kd,Binding constant for full-length NLK,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29858
sufentanil,2491,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.13,,EC50,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL658,AGONIST,Tclin,Homo sapiens,HGNC:8156
sulfaethidole,2504,RAC-alpha serine/threonine-protein kinase,Kinase,P31749,AKT1,AKT1_HUMAN,5.11,,Kd,"SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.",CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:391
sulfasalazine,2525,"Acetyl-CoA acetyltransferase, mitochondrial",Enzyme,P24752,ACAT1,THIL_HUMAN,,,,,WOMBAT-PK,,,,,,,Tbio,Homo sapiens,HGNC:93
suloctidil,2536,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.1,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
sunitinib,2544,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.07,,Kd,"Binding constant for EGFR(L858R,T790M) kinase domain",CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
sunitinib,2544,Cyclin-dependent-like kinase 5,Kinase,Q00535,CDK5,CDK5_HUMAN,5.16,,Kd,Binding constant for CDK5 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:1774
sunitinib,2544,Ribosomal protein S6 kinase beta-1,Kinase,P23443,RPS6KB1,KS6B1_HUMAN,7.32,,Kd,Binding constant for S6K1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10436
sunitinib,2544,Casein kinase II subunit alpha,Kinase,P68400,CSNK2A1,CSK21_HUMAN,7.09,,Kd,Binding constant for full-length CSNK2A1,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:2457
sunitinib,2544,Inhibitor of nuclear factor kappa-B kinase subunit alpha,Kinase,O15111,CHUK,IKKA_HUMAN,6.28,,Kd,Binding affinity to IKK-alpha,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:1974
sunitinib,2544,Serine/threonine-protein kinase ULK1,Kinase,O75385,ULK1,ULK1_HUMAN,7.64,,Kd,Binding affinity to ULK1,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:12558
tacrine,2551,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,7.91,,IC50,Inhibition of self-mediated amyloid beta (1 to 42) (unknown origin) aggregation after 24 hrs by thioflavin T fluorescence assay,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
tacrolimus,2552,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,9.02,,IC50,Inhibitory activity against macrophilin (FKBP-12),CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3942
tamoxifen,2561,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.146,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
tamoxifen,2561,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.449,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
terfenadine,2600,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.448,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
terfenadine,2600,Heat shock protein HSP 90-alpha,Cytosolic other,P07900,HSP90AA1,HS90A_HUMAN,5.46,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:5253
thioguanine,2632,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,5.258,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
thioridazine,2637,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.531,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
tianeptine,2650,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.417,,Ki,,PDSP,,,,,,,Tclin,Homo sapiens,HGNC:8156
tilidine,2663,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.1,,EC50,,WOMBAT-PK,=,1.0,SCIENTIFIC LITERATURE,,https://pubmed.ncbi.nlm.nih.gov/15627429,AGONIST,Tclin,Homo sapiens,HGNC:8156
tramadol,2711,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.8,,Ki,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1237044,AGONIST,Tclin,Homo sapiens,HGNC:8156
tranylcypromine,2715,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.6,,Ki,Inhibition of human recombinant His-tagged full length LSD1 expressed in Escherichia coli BL21 (DE3) assessed as inactivation constant preincubated for 20 mins with substrate measured after 30 mins by AmplexRed based fluorescence quenching assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
vesnarinone,2817,Transitional endoplasmic reticulum ATPase,Enzyme,P55072,VCP,TERA_HUMAN,,,,Vesnarinone binds to the D1 domain of VCP,SCIENTIFIC LITERATURE,,,,https://pubmed.ncbi.nlm.nih.gov/23393163,,,Tchem,Homo sapiens,HGNC:12666
thiamine,2832,Transketolase,Enzyme,P29401,TKT,TKT_HUMAN,,,,,WOMBAT-PK,,,,,,,Tchem,Homo sapiens,HGNC:11834
thiamine,2832,Heat shock protein HSP 90-alpha,Cytosolic other,P07900,HSP90AA1,HS90A_HUMAN,4.9,,IC50,Inhibition of recombinant Homo sapiens (human) Hsp90 alpha ATPase activity assessed as inorganic phosphate release by malachite green colorimetric method,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:5253
nicotinic acid,2835,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,4.88,,IC50,Inhibition of amyloid beta aggregation (unknown origin) after 4 hrs by thioflavin S assay in absence of Zn2+,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
zafirlukast,2855,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.24,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
zafirlukast,2855,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,5.359,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
zotarolimus,2949,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,8.48,,IC50,Inhibitory activity against FKBP12,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3942
bithionol,3032,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.651,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
bithionol,3032,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.212,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
cetrimonium,3082,Dynamin-1,Structural,Q05193,DNM1,DYN1_HUMAN,5.36,,IC50,Concentration required against dynamin-1 GTPase activity of sheep brain.,CHEMBL,=,,,,,,Tbio,Homo sapiens,HGNC:2972
diosmin,3157,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.99,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
diosmin,3157,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.99,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
flusalan,3236,Mu-type opioid receptor,GPCR,P42866,Oprm1,OPRM_MOUSE,8.07,,IC50,Ability to induce 50% of maximal effect in mouse vas deferens expressing Opioid receptor delta 1,CHEMBL,=,,,,,,,Mus musculus,MGI:97441
pentazocine,3424,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.409,,Ki,,WOMBAT-PK,=,,,,,,Tclin,Homo sapiens,HGNC:8156
quercetin,3514,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.05,,IC50,Inhibition of EGFR,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
quercetin,3514,RAC-alpha serine/threonine-protein kinase,Kinase,P31749,AKT1,AKT1_HUMAN,5.27,,IC50,Inhibition of AKT1 (unknown origin),CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:391
quercetin,3514,Casein kinase II subunit alpha,Kinase,P68400,CSNK2A1,CSK21_HUMAN,5.93,,Ki,Inhibitory constant against Zea mays CK2alpha,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:2457
quercetin,3514,Phosphatidylinositol 3-kinase regulatory subunit alpha,Kinase,P27986,PIK3R1,P85A_HUMAN,5.42,,IC50,Inhibition of PI3K,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:8979
quercetin,3514,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,5.9,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
quercetin,3514,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,5.1,,IC50,Inhibition of amyloid beta (1 to 42) aggregation (unknown origin),CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
quercetin,3514,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,5.9,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
ruboxistaurin,3533,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.29,,Kd,Binding constant for EGFR(E746-A750del) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
ruboxistaurin,3533,Protein kinase C gamma type,Kinase,P05129,PRKCG,KPCG_HUMAN,6.52,,IC50,Inhibition of Protein kinase C gamma,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:9402
ruboxistaurin,3533,Ribosomal protein S6 kinase beta-1,Kinase,P23443,RPS6KB1,KS6B1_HUMAN,6.68,,Kd,Binding constant for S6K1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10436
ruboxistaurin,3533,Casein kinase II subunit alpha,Kinase,P68400,CSNK2A1,CSK21_HUMAN,5.44,,Kd,Binding constant for full-length CSNK2A1,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:2457
rutoside,3535,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,5.67,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
rutoside,3535,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,5.67,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
ciramadol,3713,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,Mechanism of Action,SCIENTIFIC LITERATURE,,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/2572952,https://pubmed.ncbi.nlm.nih.gov/2572952,MODULATOR,Tclin,Homo sapiens,HGNC:8156
baicalin,4055,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,5.45,,IC50,Inhibition of LSD1 (unknown origin),CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
baicalin,4055,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,5.45,,IC50,Inhibition of LSD1 (unknown origin),CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
tirilazad,4063,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.69,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
tirilazad,4063,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,4.789,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
pazopanib,4118,Serine/threonine-protein kinase NLK,Kinase,Q9UBE8,NLK,NLK_HUMAN,5.36,,Kd,Binding constant for full-length NLK,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29858
pazopanib,4118,Mitogen-activated protein kinase kinase kinase 10,Kinase,Q02779,MAP3K10,M3K10_HUMAN,5.68,,Kd,Binding constant for MLK2 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:6849
gentian violet,4138,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.06,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
gentian violet,4138,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.325,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
temsirolimus,4161,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,5.75,,IC50,Inhibition of FKBP12-independent human recombinant mTOR expressed in HEK293 cells using His6-S6K1 as a substrate by DELFIA assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3942
boceprevir,4172,Lysosomal protective protein,Enzyme,P10619,CTSA,PPGB_HUMAN,6.0,,IC50,,IUPHAR,=,,,,,INHIBITOR,Tchem,Homo sapiens,HGNC:9251
telaprevir,4173,Lysosomal protective protein,Enzyme,P10619,CTSA,PPGB_HUMAN,7.0,,IC50,,IUPHAR,=,,,,,INHIBITOR,Tchem,Homo sapiens,HGNC:9251
vandetanib,4178,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.32,,Kd,Binding constant for EGFR(E746-A750del) kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL24828,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
vandetanib,4178,Ribosomal protein S6 kinase beta-1,Kinase,P23443,RPS6KB1,KS6B1_HUMAN,5.8,,Kd,Binding constant for S6K1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10436
icatibant,4186,B1 bradykinin receptor,GPCR,P46663,BDKRB1,BKRB1_HUMAN,7.0,,Ki,,IUPHAR,=,,,,,ANTAGONIST,Tchem,Homo sapiens,HGNC:1029
crizotinib,4187,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.57,,Kd,Binding constant for EGFR(G719C) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
crizotinib,4187,Inhibitor of nuclear factor kappa-B kinase subunit beta,Kinase,O14920,IKBKB,IKKB_HUMAN,5.26,,Kd,Binding constant for IKK-beta kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:5960
crizotinib,4187,Ribosomal protein S6 kinase beta-1,Kinase,P23443,RPS6KB1,KS6B1_HUMAN,6.19,,Kd,Binding constant for S6K1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10436
crizotinib,4187,Serine/threonine-protein kinase ULK1,Kinase,O75385,ULK1,ULK1_HUMAN,6.0,,Kd,Binding constant for ULK1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:12558
hydroxyprogesterone caproate,4189,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,5.501,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
ruxolitinib,4190,Inhibitor of nuclear factor kappa-B kinase subunit beta,Kinase,O14920,IKBKB,IKKB_HUMAN,5.64,,Kd,Binding constant for IKK-beta kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:5960
ruxolitinib,4190,Casein kinase II subunit alpha,Kinase,P68400,CSNK2A1,CSK21_HUMAN,5.38,,Kd,Binding constant for CSNK2A1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:2457
ruxolitinib,4190,Serine/threonine-protein kinase ULK1,Kinase,O75385,ULK1,ULK1_HUMAN,6.52,,Kd,Binding constant for ULK1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:12558
axitinib,4225,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.64,,Kd,Binding constant for EGFR(G719C) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
ingenol mebutate,4226,Protein kinase C gamma type,Kinase,P05129,PRKCG,KPCG_HUMAN,9.79,,Ki,,IUPHAR,=,,,,,ACTIVATOR,Tchem,Homo sapiens,HGNC:9402
tapentadol,4283,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,7.018,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201777,AGONIST,Tclin,Homo sapiens,HGNC:8156
Florbetapir F-18,4285,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,8.54,,Ki,,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
Flutemetamol (18F),4301,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,9.15,,Ki,Binding affinity to human amyloid beta plaque,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
afatinib,4318,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,10.0,,Kd,Binding constant for EGFR(G719C) kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1173655,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
zinc chloride,4344,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.66,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
bosutinib,4359,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.74,,Kd,Binding constant for EGFR(E746-A750del) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
bosutinib,4359,Ribosomal protein S6 kinase beta-1,Kinase,P23443,RPS6KB1,KS6B1_HUMAN,6.18,,Kd,Binding constant for S6K1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10436
bosutinib,4359,Serine/threonine-protein kinase NLK,Kinase,Q9UBE8,NLK,NLK_HUMAN,5.66,,Kd,Binding constant for NLK kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29858
bosutinib,4359,Serine/threonine-protein kinase ULK1,Kinase,O75385,ULK1,ULK1_HUMAN,5.92,,Kd,Binding constant for ULK1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:12558
cetrimide,4360,Dynamin-1,Structural,Q05193,DNM1,DYN1_HUMAN,5.24,,IC50,Concentration required against dynamin-1 GTPase activity of sheep brain.,CHEMBL,=,,,,,,Tbio,Homo sapiens,HGNC:2972
cisplatin,4392,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.582,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
cisplatin,4392,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,5.335,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
colistin,4425,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.824,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
carfilzomib,4483,Proteasome subunit beta type-1,Enzyme,P20618,PSMB1,PSB1_HUMAN,5.84,,IC50,Inhibition of human caspase-like activity of 20S constitutive proteasome preincubated for 15 mins followed by substrate addition by fluorescence assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9537
carfilzomib,4483,Proteasome subunit beta type-2,Enzyme,P49721,PSMB2,PSB2_HUMAN,6.69,,IC50,Inhibition of 20S proteasome beta2 subunit in human Jurkat cell lysate using Suc-RLR-AMC as substrate pretreated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9539
carfilzomib,4483,Proteasome subunit beta type-1,Enzyme,P20618,PSMB1,PSB1_HUMAN,5.84,,IC50,Inhibition of human caspase-like activity of 20S constitutive proteasome preincubated for 15 mins followed by substrate addition by fluorescence assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9537
diosmetin,4601,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.55,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
diosmetin,4601,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.55,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
methylnaltrexone,4616,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,7.55,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1186579,ANTAGONIST,Tclin,Homo sapiens,HGNC:8156
rose bengal,4637,Beta-galactosidase,Enzyme,P16278,GLB1,BGAL_HUMAN,4.1,,IC50,Inhibition of Beta-galactosidase,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:4298
nalfurafine,4673,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.14,,EC50,,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8156
nalfurafine,4673,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,9.26,,EC50,Inhibition of ERK1 phosphorylation (unknown origin),CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:6877
nalfurafine,4673,Mu-type opioid receptor,GPCR,P42866,Oprm1,OPRM_MOUSE,9.37,,Ki,Displacement of [3H]DAMGO from mu opioid receptor in mouse whole brain without cerebellum,CHEMBL,=,,,,,,,Mus musculus,MGI:97441
nalfurafine,4673,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,9.26,,EC50,Inhibition of ERK1 phosphorylation (unknown origin),CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:6877
sodium aurothiomalate,4706,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.624,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
cabozantinib,4715,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.65,,IC50,Inhibition of EGFR (unknown origin) by HTRF method,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
thiomersal,4733,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,6.111,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
ridaforolimus,4778,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,9.699,,IC50,"Measured as dose-dependent inhibition of phosphorylation of ribosomal protein S6, a signaling protein downstream of mTOR",SCIENTIFIC LITERATURE,=,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/21482695,https://pubmed.ncbi.nlm.nih.gov/21482695,INHIBITOR,Tclin,Homo sapiens,HGNC:3942
ibrutinib,4810,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.25,,IC50,Inhibition of ErbB1 relative to control,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
florbetaben F18,4818,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,8.65,,Ki,,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
naloxegol,4832,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,Mechanism of Action,DRUG LABEL,,1.0,DRUG LABEL,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204760s000lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204760s000lbl.pdf,ANTAGONIST,Tclin,Homo sapiens,HGNC:8156
ceritinib,4866,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.05,,IC50,Inhibition of EGFR (unknown origin) after 60 mins,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
dexrabeprazole,4867,Fatty acid synthase,Enzyme,P49327,FASN,FAS_HUMAN,5.23,,Ki,Inhibition of purified recombinant FASN TE activity (unknown origin) using 4-MUH as substrate preincubated for 30 mins before substrate addition measured after 1 hr by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3594
nintedanib,4903,Ribosomal protein S6 kinase beta-1,Kinase,P23443,RPS6KB1,KS6B1_HUMAN,6.72,,Kd,Binding constant for S6K1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10436
nintedanib,4903,Casein kinase II subunit alpha,Kinase,P68400,CSNK2A1,CSK21_HUMAN,5.12,,Kd,Binding constant for CSNK2A1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:2457
nintedanib,4903,Mitogen-activated protein kinase kinase kinase 10,Kinase,Q02779,MAP3K10,M3K10_HUMAN,5.64,,Kd,Binding constant for MLK2 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:6849
nintedanib,4903,Inhibitor of nuclear factor kappa-B kinase subunit alpha,Kinase,O15111,CHUK,IKKA_HUMAN,5.35,,Kd,Binding constant for IKK-alpha kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:1974
nintedanib,4903,Serine/threonine-protein kinase ULK1,Kinase,O75385,ULK1,ULK1_HUMAN,6.47,,Kd,Binding constant for ULK1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:12558
lenvatinib,4942,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.187,,IC50,in vitro kinase activity at 1uM ATP,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/17943726,,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
cetuximab,4954,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.41,,Kd,,IUPHAR,=,1.0,DRUG LABEL,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s063lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s063lbl.pdf,ANTIBODY BINDING,Tclin,Homo sapiens,HGNC:3236
panitumumab,4955,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,10.3,,Kd,,IUPHAR,=,1.0,DRUG LABEL,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf,AGONIST,Tclin,Homo sapiens,HGNC:3236
eluxadoline,5001,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.77,,Ki,Recombinantly expressed human mu OR,SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/22671931,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206940s000lbl.pdf,AGONIST,Tclin,Homo sapiens,HGNC:8156
tannic acid,5039,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,5.39,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:6877
osimertinib,5062,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.824,,IC50,Inhibition of EGFR phosphorylation in double mutant cell line H1975,SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/25271963,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
ixazomib,5067,Proteasome subunit beta type-1,Enzyme,P20618,PSMB1,PSB1_HUMAN,7.509,,IC50,,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/20160034,,INHIBITOR,Tclin,Homo sapiens,HGNC:9537
ixazomib,5067,Proteasome subunit beta type-2,Enzyme,P49721,PSMB2,PSB2_HUMAN,5.456,,IC50,,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/20160034,,INHIBITOR,Tclin,Homo sapiens,HGNC:9539
necitumumab,5071,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.49,,Kd,Binding affinity of whole IMC-11F8 IgG using BIAcore sensor technology.,IUPHAR,=,1.0,DRUG LABEL,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf,ANTIBODY BINDING,Tclin,Homo sapiens,HGNC:3236
migalastat,5110,Beta-galactosidase,Enzyme,P16278,GLB1,BGAL_HUMAN,4.05,,IC50,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:4298
chromic chloride,5118,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.53,,IC50,,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
icotinib,5209,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.699,,IC50,,SCIENTIFIC LITERATURE,=,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/22959248,https://pubmed.ncbi.nlm.nih.gov/22088449,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
olmutinib,5210,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.036,,IC50,HCC827 cells expressing EGFR(DEL19),SCIENTIFIC LITERATURE,=,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/27357069,https://pubmed.ncbi.nlm.nih.gov/27357069,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
naldemedine,5220,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.95,,Ki,,IUPHAR,=,1.0,DRUG LABEL,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf,ANTAGONIST,Tclin,Homo sapiens,HGNC:8156
midostaurin,5231,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.06,,Kd,"Binding constant for EGFR(L858R,T790M) kinase domain",CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
midostaurin,5231,RAC-alpha serine/threonine-protein kinase,Kinase,P31749,AKT1,AKT1_HUMAN,6.02,,Kd,Binding constant for AKT1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:391
midostaurin,5231,Inhibitor of nuclear factor kappa-B kinase subunit beta,Kinase,O14920,IKBKB,IKKB_HUMAN,5.2,,Kd,Binding constant for IKK-beta kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:5960
midostaurin,5231,Ribosomal protein S6 kinase beta-1,Kinase,P23443,RPS6KB1,KS6B1_HUMAN,5.89,,Kd,Binding constant for S6K1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10436
midostaurin,5231,Casein kinase II subunit alpha,Kinase,P68400,CSNK2A1,CSK21_HUMAN,6.6,,Kd,Binding constant for full-length CSNK2A1,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:2457
midostaurin,5231,Mitogen-activated protein kinase kinase kinase 10,Kinase,Q02779,MAP3K10,M3K10_HUMAN,6.1,,Kd,Binding constant for MLK2 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:6849
midostaurin,5231,Inhibitor of nuclear factor kappa-B kinase subunit alpha,Kinase,O15111,CHUK,IKKA_HUMAN,5.42,,Kd,Binding affinity to IKK-alpha,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:1974
brigatinib,5233,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.174,,IC50,,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/27780853,,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
neratinib,5252,Mitogen-activated protein kinase kinase kinase 10,Kinase,Q02779,MAP3K10,M3K10_HUMAN,5.34,,Kd,Binding constant for MLK2 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:6849
neratinib,5252,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.036,,IC50,,SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/15715478,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
copanlisib,5256,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,7.35,,IC50,,IUPHAR,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:3942
dacomitinib,5297,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.222,,IC50,ELISA-Based erbB Kinase Assay with 20 uM [ATP],SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/30506139,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
fedratinib,5347,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.24,,Kd,Binding constant for EGFR(T790M) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
fedratinib,5347,Inhibitor of nuclear factor kappa-B kinase subunit beta,Kinase,O14920,IKBKB,IKKB_HUMAN,6.44,,Kd,Binding constant for IKK-beta kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:5960
fedratinib,5347,Ribosomal protein S6 kinase beta-1,Kinase,P23443,RPS6KB1,KS6B1_HUMAN,5.7,,Kd,Binding constant for S6K1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10436
fedratinib,5347,Casein kinase II subunit alpha,Kinase,P68400,CSNK2A1,CSK21_HUMAN,6.04,,Kd,Binding constant for CSNK2A1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:2457
fedratinib,5347,Mitogen-activated protein kinase kinase kinase 10,Kinase,Q02779,MAP3K10,M3K10_HUMAN,5.16,,Kd,Binding constant for MLK2 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:6849
fedratinib,5347,Inhibitor of nuclear factor kappa-B kinase subunit alpha,Kinase,O15111,CHUK,IKKA_HUMAN,6.08,,Kd,Binding constant for IKK-alpha kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:1974
fedratinib,5347,Serine/threonine-protein kinase ULK1,Kinase,O75385,ULK1,ULK1_HUMAN,6.57,,Kd,Binding constant for ULK1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:12558
brilliant Blue G,5359,Alpha-synuclein,Transporter,P37840,SNCA,SYUA_HUMAN,5.27,,IC50,Inhibition of wild type alpha-synuclein (unknown origin) aggregation expressed in Escherichia coli BL21 after 30 days by thioflavin T staining-based spectrofluorimetric analysis,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:11138
bempedoic acid,5382,ATP-citrate synthase,Enzyme,P53396,ACLY,ACLY_HUMAN,5.69,,Ki,Inhibition of ACL by ETC-1002-CoA,SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/27892461,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:115
selumetinib,5388,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.66,,Kd,Binding constant for EGFR(T790M) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
tucatinib,5389,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.35,,IC50,Inhibition of enzyme activity in a biochemical assay.,IUPHAR,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
oliceridine,5406,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.22,,Ki,Mechanism of Action,DRUG LABEL,=,1.0,DRUG LABEL,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210730s000lbl.pdf,AGONIST,Tclin,Homo sapiens,HGNC:8156
trilaciclib,5442,Cyclin-dependent-like kinase 5,Kinase,Q00535,CDK5,CDK5_HUMAN,5.83,,IC50,,DRUG LABEL,=,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000PharmR.pdf,,INHIBITOR,Tchem,Homo sapiens,HGNC:1774
samidorphan,5460,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,10.28,,Ki,Possible target for the mechanism of action of the drug,DRUG LABEL,=,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf,,ANTAGONIST,Tclin,Homo sapiens,HGNC:8156
